Amplicon was formed to further utilize RDA in the search for cancer-related genes. In October 1997, Amplicon was acquired by biotech leader Tularik, Inc. At the time Tularik was the largest privately held biotechnology company in the nation, and its scientists are enthusiastic about continuing collaborations with CSHL scientists while using RDA in an extensive cancer research program. Tularik was itself then subsequently acquired by Amgen in July 2003.
